Cargando…

Bioassay Guided Isolation and Docking Studies of a Potential β-Lactamase Inhibitor from Clutia myricoides

Infectious diseases are the second major cause of death worldwide, and the ability to resist multiple classes of antibiotics is the key factor in enabling pathogenic organisms to survive and spread in the nosocomial environment. Unfortunately, the available β-lactamase inhibitors are not efficient a...

Descripción completa

Detalles Bibliográficos
Autores principales: Elfaky, Mahmoud A., El-Halawany, Ali M., Koshak, Abdulrahman E., Alshali, Khalid Z., El-Araby, Moustafa E., Khayat, Maan T., Abdallah, Hossam M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321312/
https://www.ncbi.nlm.nih.gov/pubmed/32486455
http://dx.doi.org/10.3390/molecules25112566
_version_ 1783551435562024960
author Elfaky, Mahmoud A.
El-Halawany, Ali M.
Koshak, Abdulrahman E.
Alshali, Khalid Z.
El-Araby, Moustafa E.
Khayat, Maan T.
Abdallah, Hossam M.
author_facet Elfaky, Mahmoud A.
El-Halawany, Ali M.
Koshak, Abdulrahman E.
Alshali, Khalid Z.
El-Araby, Moustafa E.
Khayat, Maan T.
Abdallah, Hossam M.
author_sort Elfaky, Mahmoud A.
collection PubMed
description Infectious diseases are the second major cause of death worldwide, and the ability to resist multiple classes of antibiotics is the key factor in enabling pathogenic organisms to survive and spread in the nosocomial environment. Unfortunately, the available β-lactamase inhibitors are not efficient against β-lactamase B, C, and D which necessitates discovering either broad spectrum β-lactamase inhibitors or new β-lactam antibiotics resistant to bacterial enzymes. In this regard, products of natural origin have prompted the disclosure of new compounds and medicinal leads. Chloroform fraction of Clutia myricoides (Soa’bor) showed a pronounced activity against extended-spectrum β-lactamase (ESBL) strains. Bio-guided fractionation resulted in isolation of two new compounds; 2-methoxy chrysophanol (2) and Saudin-I (5) in addition to three known compounds that were identified as chrysophanol (1), stigmasterol (3) and β-sitosterol (4). Antibacterial and anti ESBL activities of the isolated compounds were performed. No antibacterial activities were detected for any of the tested compounds. Meanwhile, compound 2 showed promising anti ESBL activity. Compound 2 has shown an obvious activity against K. pneumoniae ATCC 700603 with a marked enlargement of inhibition zones (>5mm) in combination with third generation cephalosporin antibiotics. To further understand the mechanism of action of compound 2, molecular docking was carried out against CTX-M-27 ESBL. The results showed binding site interactions strikingly different from its analogue, compound 1, allowing compound 2 to be active against ESBL. These results proposed the concomitant use of these active compounds with antibiotics that would increase their efficiency. Nevertheless, the interaction between this active compound and antibiotics should be taken into consideration. Therefore, in order to evaluate the safety of this active compound, further in vitro and in vivo toxicity assays must be carried out.
format Online
Article
Text
id pubmed-7321312
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73213122020-06-29 Bioassay Guided Isolation and Docking Studies of a Potential β-Lactamase Inhibitor from Clutia myricoides Elfaky, Mahmoud A. El-Halawany, Ali M. Koshak, Abdulrahman E. Alshali, Khalid Z. El-Araby, Moustafa E. Khayat, Maan T. Abdallah, Hossam M. Molecules Article Infectious diseases are the second major cause of death worldwide, and the ability to resist multiple classes of antibiotics is the key factor in enabling pathogenic organisms to survive and spread in the nosocomial environment. Unfortunately, the available β-lactamase inhibitors are not efficient against β-lactamase B, C, and D which necessitates discovering either broad spectrum β-lactamase inhibitors or new β-lactam antibiotics resistant to bacterial enzymes. In this regard, products of natural origin have prompted the disclosure of new compounds and medicinal leads. Chloroform fraction of Clutia myricoides (Soa’bor) showed a pronounced activity against extended-spectrum β-lactamase (ESBL) strains. Bio-guided fractionation resulted in isolation of two new compounds; 2-methoxy chrysophanol (2) and Saudin-I (5) in addition to three known compounds that were identified as chrysophanol (1), stigmasterol (3) and β-sitosterol (4). Antibacterial and anti ESBL activities of the isolated compounds were performed. No antibacterial activities were detected for any of the tested compounds. Meanwhile, compound 2 showed promising anti ESBL activity. Compound 2 has shown an obvious activity against K. pneumoniae ATCC 700603 with a marked enlargement of inhibition zones (>5mm) in combination with third generation cephalosporin antibiotics. To further understand the mechanism of action of compound 2, molecular docking was carried out against CTX-M-27 ESBL. The results showed binding site interactions strikingly different from its analogue, compound 1, allowing compound 2 to be active against ESBL. These results proposed the concomitant use of these active compounds with antibiotics that would increase their efficiency. Nevertheless, the interaction between this active compound and antibiotics should be taken into consideration. Therefore, in order to evaluate the safety of this active compound, further in vitro and in vivo toxicity assays must be carried out. MDPI 2020-05-31 /pmc/articles/PMC7321312/ /pubmed/32486455 http://dx.doi.org/10.3390/molecules25112566 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Elfaky, Mahmoud A.
El-Halawany, Ali M.
Koshak, Abdulrahman E.
Alshali, Khalid Z.
El-Araby, Moustafa E.
Khayat, Maan T.
Abdallah, Hossam M.
Bioassay Guided Isolation and Docking Studies of a Potential β-Lactamase Inhibitor from Clutia myricoides
title Bioassay Guided Isolation and Docking Studies of a Potential β-Lactamase Inhibitor from Clutia myricoides
title_full Bioassay Guided Isolation and Docking Studies of a Potential β-Lactamase Inhibitor from Clutia myricoides
title_fullStr Bioassay Guided Isolation and Docking Studies of a Potential β-Lactamase Inhibitor from Clutia myricoides
title_full_unstemmed Bioassay Guided Isolation and Docking Studies of a Potential β-Lactamase Inhibitor from Clutia myricoides
title_short Bioassay Guided Isolation and Docking Studies of a Potential β-Lactamase Inhibitor from Clutia myricoides
title_sort bioassay guided isolation and docking studies of a potential β-lactamase inhibitor from clutia myricoides
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321312/
https://www.ncbi.nlm.nih.gov/pubmed/32486455
http://dx.doi.org/10.3390/molecules25112566
work_keys_str_mv AT elfakymahmouda bioassayguidedisolationanddockingstudiesofapotentialblactamaseinhibitorfromclutiamyricoides
AT elhalawanyalim bioassayguidedisolationanddockingstudiesofapotentialblactamaseinhibitorfromclutiamyricoides
AT koshakabdulrahmane bioassayguidedisolationanddockingstudiesofapotentialblactamaseinhibitorfromclutiamyricoides
AT alshalikhalidz bioassayguidedisolationanddockingstudiesofapotentialblactamaseinhibitorfromclutiamyricoides
AT elarabymoustafae bioassayguidedisolationanddockingstudiesofapotentialblactamaseinhibitorfromclutiamyricoides
AT khayatmaant bioassayguidedisolationanddockingstudiesofapotentialblactamaseinhibitorfromclutiamyricoides
AT abdallahhossamm bioassayguidedisolationanddockingstudiesofapotentialblactamaseinhibitorfromclutiamyricoides